BioCentury | Sep 3, 2019
Preclinical News

Insilico, WuXi AppTec unveil one piece of hit-generating AI pipeline

Insilico and WuXi AppTec's Nature Biotechnology study provides initial proof-of-concept for the AI company's de novo small molecule generation platform, but the companies have not yet revealed their methods for taking on orphan targets with...
BioCentury | Nov 28, 2018
Emerging Company Profile

Cybrexa: pH-based tumor targeting

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors. Cybrexa...
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

Akrevia Therapeutics LLC parlayed preclinical proof-of-concept data from its tumor-activated therapies into a $30 million series A round co-led by Atlas Venture and F-Prime Capital Partners. Akrevia, which emerged from stealth on Sept. 27, uses...
BioCentury | Nov 4, 2016
Company News

Designed Biologics, NuvoBio deal

...Designed Biologics partnered to develop synthetic small peptides to treat prostate cancer. NuvoBio will fund and Designed Biologics...
...rights to IP and products resulting from the deal. Designed Biologics declined to disclose financial terms. Designed Biologics Inc....
Items per page:
1 - 4 of 4
BioCentury | Sep 3, 2019
Preclinical News

Insilico, WuXi AppTec unveil one piece of hit-generating AI pipeline

Insilico and WuXi AppTec's Nature Biotechnology study provides initial proof-of-concept for the AI company's de novo small molecule generation platform, but the companies have not yet revealed their methods for taking on orphan targets with...
BioCentury | Nov 28, 2018
Emerging Company Profile

Cybrexa: pH-based tumor targeting

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors. Cybrexa...
BioCentury | Sep 28, 2018
Finance

Activating Akrevia

Akrevia Therapeutics LLC parlayed preclinical proof-of-concept data from its tumor-activated therapies into a $30 million series A round co-led by Atlas Venture and F-Prime Capital Partners. Akrevia, which emerged from stealth on Sept. 27, uses...
BioCentury | Nov 4, 2016
Company News

Designed Biologics, NuvoBio deal

...Designed Biologics partnered to develop synthetic small peptides to treat prostate cancer. NuvoBio will fund and Designed Biologics...
...rights to IP and products resulting from the deal. Designed Biologics declined to disclose financial terms. Designed Biologics Inc....
Items per page:
1 - 4 of 4